UNSPSC 51162032: Guaifenesin/oxtriphylline

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162032 Guaifenesin/oxtriphylline is a Commodity code nominally describing a specific pharmaceutical combination, but recent state and local opportunities tagged under this code do not involve guaifenesin or oxtriphylline products. Instead, the code shows activity in pharmaceutical procurement and on-site pharmacy services — a mismatch that signals the code sees little relevant recent activity aligned with its stated scope. The two recent opportunities involve naloxone and drug deactivation systems (Seminole County, Florida) and comprehensive on-site pharmacy services including formulary stocking and dispensing (Hall County, Georgia). These procurements center on broader pharmaceutical management and emergency-response medications rather than the specific therapeutic agent the code nominally describes.

Seminole County in Florida and Hall County in Georgia represent the geographic spread visible in recent activity, with no additional states represented in the available opportunities. Seminole County issued an IFB (Solicitation Number IFB60459723LAS, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford; Hall County issued an RFQ/P (RFQ/P #47-010, due June 4, 2026) seeking a single vendor to provide on-site pharmacy services to approximately 3,005 eligible individuals enrolled in the county's group health insurance plans, with technical qualifications weighted at 80 percent and cost at 20 percent. Neither solicitation specifies set-asides for disadvantaged enterprises. The code shows limited recent activity, and the tagged opportunities suggest misclassification rather than genuine procurement under the guaifenesin/oxtriphylline commodity heading.